There are currently 145 active clinical trials seeking participants for Pancreatic Cancer research studies. The states with the highest number of trials for Pancreatic Cancer participants are California, New York, Illinois and Texas.
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT05215574
Recruiting
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: NGM Clinical Study Site, Gilbert, Arizona +8 locations
Conditions: Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Register for Updates
The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response
NCT06050395
Recruiting
The purpose of the study is to evaluate the feasibility and acceptability of a remote nutrition coaching and monitoring intervention during the 12-weeks of active chemotherapy for borderline resectable and locally advanced pancreatic cancer participants.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pancreatic Cancer
Register for Updates
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
NCT06001268
Recruiting
The purpose of the study is to assess the feasibility and participant satisfaction with the Support through Remote Observation and Nutrition Guidance program. The program provides enhanced dietician access and nutrition support for participants living with pancreatic cancer who are undergoing surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pancreatic Cancer
Register for Updates
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT04477343
Recruiting
The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: University of Rochester, Rochester, New York
Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Register for Updates
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT03065062
Recruiting
This research study is studying a combination of drugs as a possible treatment for cancer that might have a specific change in the phosphatidylinositol-3 phosphate (PI3K) pathway.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer, Pancreatic Cancer
Register for Updates
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
NCT02705196
Recruiting
The purpose of this study is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer. The study will also evaluate whether or not intratumoral injection of LOAd703 will support current standard of care treatment to reduce the size of the tumor and improve survival of the patients. Adenoviruses are known as the "common cold" virus and most individuals have had multiple infections during their lifetime. Oncolytic adenoviruses are adenoviruses that are mo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: Baylor College of Medicine, Houston, Texas +1 locations
Conditions: Pancreatic Cancer
Register for Updates
Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer
NCT06141031
Recruiting
To evaluate the safety, tolerability, and efficacy of TTI-101 given in combination with Stereotactic Body Radiation Therapy (SBRT) in borderline resectable pancreatic ductal adenocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: University of Colorado, Aurora, Colorado
Conditions: Pancreatic Cancer
Register for Updates
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT03454035
Recruiting
This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4/6 inhibitor palbociclib.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
01/24/2024
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Tumor, Solid, Pancreatic Cancer, Melanoma
Register for Updates
CAR T Cell Immunotherapy for Pancreatic Cancer
NCT03323944
Recruiting
Phase I study to establish the safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells in patients with histologically confirmed unresectable or metastatic pancreatic adenocarcinoma
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pancreatic Cancer, Cancer of the Pancreas
Register for Updates
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
NCT05776524
Recruiting
The objective of this research is to find out what effects (good and bad), the combination of gemcitabine and nab-paclitaxel therapy (GEM-ABR for the rest of the document), standard chemotherapy for pancreatic cancer, and the TheraBionic device has on participants' condition.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Pancreatic Cancer, Metastatic Adenocarcinoma
Register for Updates
Switch Maintenance in Pancreatic
NCT05419479
Recruiting
This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body. This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells. The names of the study drugs involved in this study are: Domvanalimab (also known as AB154) Zimberelimab (also known as AB122) APX005M
Gender:
All
Ages:
18 years and above
Trial Updated:
01/16/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas, Adenosquamous Carcinoma of the Pancreas
Register for Updates
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
NCT05461430
Recruiting
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/02/2024
Locations: xCures, Oakland, California
Conditions: Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Register for Updates